FEATURES OF THE CORRELATION OF POST-STROKE COGNITIVE DISORDERS

Karimov B.B.

Authors

Karimov B.B. Department of Neurology Andijan State Medical Institute Uzbekistan, Andijan

Keywords:

Disability, ischemic stroke, clexane, lipid peroxidation, thrombolytic agents, thrombolytic therapy, cognitive disorders.

Abstract

The article presents the main directions, indications and contraindications, methods of using thrombolytic therapy in patients during the acute period of ischemic stroke. The pathogenesis of the development of cerebral infarction is considered, and a comparative description of direct and indirect anticoagulants is provided. The article examines cognitive disorders against the background of ischemic stroke and the relationship after treatment with thrombolytic treatment

References

Gusev E.I., Bogolepova A.N. Cognitive impairment in cerebrovascular diseases. Moscow: MEDpress-inform 2012; 160.

Gusev E.I., Skvortsova V.I. Cerebral ischemia. Moscow: Medicine 2001; 327.

Gusev E.I., Skvortsova V.I., Stakhovskaya L.V. Epidemiology of stroke in Russia. Journal of Neurol and psychiath (Appendix "Stroke) 2003; 8: 4-9.

Duplenkova Yu.A., Ippolitova E.V. Aspects of neuropsychological rehabilitation of patients with ONMC in the acute period, depending on the localization of the focus. V International Congress "Neurorehabilitation-2013". 2013; 93-94.

Dyakonov M.M., Shabanov P.D. On the neuroprotective effect of peptide drugs. Vestn Ros voen-med akad 2011; 1: 33: 255-258.

Zakharov V.V., Kovtun A.Yu. Diagnosis of vascular cognitive disorders. M 2011; 16.

Zakharov V.V. Neuropsychological tests. Necessity and possibility of application. Consilium Medicum 13: 2: 82-90.

Levin O.S., Dudarova M.A., Usoltseva N.I. Diagnosis and treatment of post-stroke cognitive impairment. Consilium Medicum 2010; 2: 12: 5

Lee HJ, Kang JS, Kim YI. Citicoline protects against cognitive impairment in a rat model of chronic cerebral hypoperfusion. J Clin Neurol, 2009, 5: 33-38.

Barba R, Martinez-Espinosa S, Rodriquez-Garcia E et al. Poststroke dementia: clinical features and risk factors. Stroke, 2000, 31: 1494–1501.

Pohjasvaara T, Erkinjuntti T, Vataja R, Kaste M. Dementia three months after stroke: baseline frequency and effect of different definitions for dementia in the Helsinki Aging Memory Study (SAM) cohort. Stroke, 1997, 28: 785–792.

Kase CS, Wolf PA, Kelly-Hayes M et al. Intellectual decline after stroke. The Framingham study. Stroke, 1998, 29: 805–812. 10. Leys D, Неnon H, Mackowiak-Cordoliani MA, Pasquier F. Poststroke dementia. Lancet Neurol, 2005, 752-759.

Warach S, Pettigrew LC, Dashe JF, Pullicino P, Lefkowitz DM, Sabounjian L, Harnett K, Schwiderski U, Gammans R. Effect of citicoline on ischemic lesions as measured by diffusionweighted magnetic resonance imaging. Citicoline 010 Investigators. Ann Neuro, 2000, 48: 713–722.